4 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
71 citations
,
November 2012 in “Expert Opinion on Drug Safety” 5-alpha reductase inhibitors can cause sexual side effects like erectile dysfunction and reduced sexual desire, sometimes lasting after stopping the drug.
Mycophenolate mofetil is a good alternative for autoimmune hepatitis patients who can't tolerate azathioprine.
14 citations
,
July 1987 in “Dermatologic Clinics” The document concludes that treating female hair loss should target reducing excess androgen and blocking its effects on hair follicles, with the best treatments being hormonal therapy, adrenal suppression, and topical minoxidil.
September 2020 in “Zenodo (CERN European Organization for Nuclear Research)” Indometacin was chosen for a gel to help treat mastopathy and prevent breast cancer.
2 citations
,
March 2015 in “Clinical and Experimental Dermatology” Azathioprine can cause unusual hair loss, which may reverse after stopping the drug.
6 citations
,
November 2017 in “Dermatologic Therapy” Combining mometasone furoate cream with adapalene gel is safer and more effective for hair regrowth in alopecia areata than using the cream alone.
July 2025 in “American Journal of Clinical Dermatology” Alopecia treatments like 5α-reductase inhibitors and spironolactone are safe for breast cancer patients and high-risk women.
October 2024 in “Journal of the Endocrine Society” Surgical removal of a rare ovarian tumor improved symptoms and hormone levels in a postmenopausal woman.
36 citations
,
November 2020 in “Journal of The European Academy of Dermatology and Venereology” 5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
31 citations
,
September 2020 in “Clinical endocrinology” Some antiandrogens may lower testosterone better than others, but it's unclear which is best for feminization in transgender women; more research is needed.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Androgenetic alopecia (AGA) is a common genetic condition affecting the scalp, caused by the conversion of testosterone to Dihydrotestosterone (DHT) by the enzyme 5-Alpha Reductase, leading to hair follicle shrinkage. Current FDA-approved treatments, finasteride and minoxidil, have limitations, prompting research into nanocarrier-based drug delivery systems like liposomes, solid lipid nanoparticles, and transferosomes. These systems offer improved drug stability, targeted delivery, and sustained release while minimizing systemic exposure. Innovations such as antioxidant formulations and spironolactone-loaded nanoparticles aim to reduce oxidative stress and block androgen receptors. Although preclinical results are promising, challenges remain in clinical translation, including the need for reliable trials, funding, and regulatory approval. The review highlights the importance of clinical validation and scalable production to harness nanotechnology's potential for AGA treatment.
31 citations
,
September 2006 in “The Journal of Clinical Endocrinology & Metabolism” Testosterone therapy may slightly improve sexual function in postmenopausal women, but its long-term safety is unknown.
1 citations
,
January 2020 in “Surgical & Cosmetic Dermatology” Combining oral minoxidil with JAK inhibitors helps regrow hair in severe alopecia areata cases.
7 citations
,
February 2024 in “The Journal of Physiology” Reduced plakoglobin and steroid abuse increase the risk of heart rhythm issues.
149 citations
,
June 2002 in “British Journal of Dermatology” Minoxidil works better for female hair loss, but cyproterone reduces scalp oiliness and causes menstrual issues.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
September 2025 in “Journal of Medicinal Chemistry” AR-27 E-Chol siRNA can effectively regrow hair by reducing androgen receptor gene activity.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Androgenetic alopecia (AGA) is a common genetic condition affecting the scalp, caused by the conversion of testosterone to Dihydrotestosterone (DHT) by the enzyme 5-Alpha Reductase, leading to hair follicle shrinkage. Current FDA-approved treatments, finasteride and minoxidil, have limitations, prompting research into nanocarrier-based drug delivery systems like liposomes, solid lipid nanoparticles, and transferosomes. These systems offer improved drug stability, targeted delivery, and sustained release while minimizing systemic exposure. Innovations such as antioxidant formulations and spironolactone-loaded nanoparticles aim to reduce oxidative stress and block androgen receptors. Despite promising preclinical outcomes, challenges remain in clinical translation, including the need for reliable trials, funding, and regulatory approval. The review highlights the importance of clinical validation and scalable production to harness nanotechnology's potential for AGA treatment.
8 citations
,
June 2017 in “Steroids” New chemical compounds were made that effectively block an enzyme linked to prostate growth.
November 2025 in “Revista Políticas Públicas & Cidades” Microagulhamento e intradermoterapia juntos melhoram o crescimento capilar em mulheres menopausadas.
3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
16 citations
,
September 1990 in “Fertility and sterility” Ketoconazole can treat ovarian hyperandrogenism but should be used cautiously with monitoring and birth control.
35 citations
,
June 2018 in “Urology” The review suggests younger men taking 1 mg finasteride report more side effects, including sexual, skin, metabolic, and psychological issues.
The levels of zinc, vitamin D, ferritin, and selenium are different in people with androgenic alopecia compared to a control group.
113 citations
,
April 1999 in “The Journal of Clinical Endocrinology and Metabolism” Cyproterone acetate-estrogen most effective for hirsutism, but consider side effects and patient needs.
14 citations
,
January 1980 in “Dermatology” Cyproterone acetate temporarily reduces hair growth in women with idiopathic hirsutism but doesn't change hormone levels.
21 citations
,
August 1984 in “BJOG An International Journal of Obstetrics & Gynaecology” Ovarian function was similar in both treatment groups, but both caused excessive hair growth.
20 citations
,
June 1985 in “Toxicologic Pathology” Some steroid-induced health issues in rodents improved after stopping treatment, but hair loss and eye problems did not.
19 citations
,
October 2018 in “PLOS ONE” 5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.